Perioperative lenvatinib/pembrolizumab shows promise in non-metastatic ccRCC
"The combination demonstrated clinical activity and an acceptable safety profile in the perioperative setting for locally advanced, non-metastatic clear cell RCC," says Mehmet Asim Bilen, MD.
Phase 2 trial launches of combination immunotherapy for mCRPC
Study findings highlight gender gaps in oncology authorship and citation
ORIC-944 shows promise in combination with AR inhibitors in mCRPC
ASCO 2025: What to watch for in GU oncology